TY  - JOUR
AU  - Rathke, Hendrik
AU  - Holland-Letz, Tim
AU  - Mier, Walter
AU  - Flechsig, Paul
AU  - Mavriopoulou, Eleni
AU  - Röhrich, Manuel
AU  - Kopka, Klaus
AU  - Hohenfellner, Markus
AU  - Giesel, Frederik L
AU  - Haberkorn, Uwe A
AU  - Kratochwil, Clemens
TI  - Response prediction of 177Lu-PSMA-617 RLT using PSA, Chromogranin A, and LDH.
JO  - Journal of nuclear medicine
VL  - 61
IS  - 5
SN  - 2159-662X
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2019-02503
SP  - 689-695
PY  - 2020
N1  - 2020 May;61(5):689-695
AB  - Neuroendocrine-like trans-differentiation of prostate cancer adenocarcinomas correlates with serum levels of Chromogranin A (CgA) and drives treatment resistance. Aim of this work was to evaluate whether CgA could serve as a response predictor for 177Lu-PSMA617 radio-ligand therapy (PSMA-RLT) in comparison to the established tumor markers. Methods: 100 consecutive patients with metastasized castration resistant prostate cancer (mCRPC) scheduled for PSMA-RLT were evaluated for prostate specific antigen (PSA), lactate dehydrogenase (LDH) and CgA at baseline and in follow-up of PSMA-RLT. Tumor-uptake of PSMA-ligand, a known predictive marker for response, was assessed as a control-variable. Results: From the 100 evaluated patients, 35 had partial remission (PR), 16 stable disease (SD), 15 mixed response (MR) and 36 progression of disease (PD). High tumor-uptake (above salivary gland uptake) translated into PR with an Odds Ratio (OR) of 60.265 (95
LB  - PUB:(DE-HGF)16
C6  - pmid:31653712
DO  - DOI:10.2967/jnumed.119.231431
UR  - https://inrepo02.dkfz.de/record/147386
ER  -